• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to benzodiazepine compounds of the formula: <IMAGE> wherein R5 is C1-C4 alkyl, R3 is C1-C4 alkyl, and R4 is selected from Cl and F, and medicaments containing such benzodizepine compounds.
    公开号:SU888820A3
    申请号:SU802867754
    申请日:1980-01-10
    公开日:1981-12-07
    发明作者:Демарн Анри；Алло Андре
    申请人:К.М.Эндюстри(Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING BENZODIAZEPINE DERIVATIVES The invention relates to a method for producing new benzodiazepine derivatives having valuable pharmaceutical properties. The purpose of the invention is to obtain new, useful compounds expanding the arsenal of means of influence on a living organism is achieved by synthesizing the latter, based on the known condensation reaction of an amine with isocyanate 1. A method is proposed for the preparation of benodiazepine derivatives of the general formula 0 (4 .0 T-CN .CH-COOCjHj where R is bromine, chlorine or fluorine, which consists in the fact that 1 N-unsubstituted benzodiazepine derivative of the general formula H I O 1 G-C. CH-COOC Hc where R is the above values, is reacted with methyl isocyanate in the environment of benzene and In the presence of para-toluenesulfonic acid as a catalyst at the boiling point of the reaction mixture. The desired product is isolated by known methods. Example 1. CHLOR-7-CHLOR-2-phenyl-5-ethoxycarbonyl-3-methyl-carbamoyl-1-oxo-2-dihydro-2 , 3-1H-benzodiazepine, code number CM 7119. Within 30 minutes, 2 g of chloro-7-ztoxycarbonyl-3- (chloro-2-phenyl) -5-oxg) -2-DIGIDRO-2, 3-1H-benzodiazepine -1, 4, and 0.14 g of para-toluenesulfonic acid in a VO ml of benzene-free benzene are heated at the boil, then 8.4 MJI methyl isocyanate is added and heated again at kg 3 for 7 h.
    After cooling, the benzene solution is mixed for 15 minutes with an aqueous 10% sodium bicarbonate solution. Ether is added and the organic layer is separated, dried on sodium sulfate, evaporated to dryness and the residue is taken up in hot cyclohexane and left to crystallize. A colorless solid is obtained (1.2 g, 52%). Melting point according to Kofler 155 ° C. With decomposition.
    Example 2, Chloro-7- {fluoro-2-phenyl) -5-ethoxycarbonyl-3-methyl-carbamoyl-1-oxo-2-dihydro-2, 3-1H-benzodiazepine, code number CM 712
    The process is carried out according to example 1, but replacing the original benzodiazepkn with a product of formula (11), in which R is fluorine.
    A colorless solid solid with a Kofler melting point (ether) is obtained. Yield 65%.
    The products according to the invention are subjected to pharmacological tests in order to determine their activity when acting on the central nervous system. Below are the data
    In all cases, products are administered by mouth.
    Spontaneous actographies.
    Animals are placed in individual cells, intersected by two rays, which come from two photocells. During their movement, animals (mice) are hit by rays, and this is recorded by impulse counters.
    Changes in mobility of treated animals are expressed in% relative to control animals: the minus sign indicates a decrease (in percent) of the mobility of objects.,
    Tensile stress test
    The ability of animals (mice) to restore motor ability on a horizontal rod captured by the front arms is studied.
    This test shows a calming or debilitating effect on the striped muscle.
    The results are expressed in effective. a dose of 50 (flBjjj), representing the dose (mg / kg) for which 50% of mice cannot perform reconnaissance
    Rotary rod body balance test.
    Normal animals (mice), placed on a horizontal rod, driven into rotational motion do not fall.
    Results are expressed in an effective dose of 50 (flSj), representing
    a dose (in mg / kg) for which 50% of the mice fall during the test.
    Anticonvulsant activity in relation to pentetrazole.
    Injected into the peritoneum at a dose of 125 mg / kg pentylenetetrazol (or cardiazole) causes the appearance of fatal convulsions in 100% of treated mice.
    The active substances introduced by the oral route, prior to cardiazole, counteract the occurrence of convulsions and, in certain cases, ensure the survival of experimental animals.
    Results are expressed in DE} -, i.e. in a dose (in mg / kg) protecting 50% of animals.
    Anticonvulsant activity against electroshock.
    An alternating current of 12.5 volts is applied for 0.5 s with the help of corneal electrodes to groups of 12 mice that have been treated for 1 hour with the test substance. The untreated mice subjected to electroshock have a convulsion of intentional spasm. For treated mice, the number of mice that do not have convulsions is noted, and in this way the percentage of protection against convulsions is determined.
    The result gives an effective dose (DE5o) f representing the dose (mg / mg) for which 50% of the mice do not have convulsions.
    Anxiolytic activity test with 4 plates.
    The device represents a camera in the form of a parallelepipid, the floor of which is formed by 4 metal plates of equal area. Between each plate, the experimenter can create a potential difference that corresponds to a current of 0.35 mA of a duration of 0.2 s. Each time only one mouse passes from one plate to another and receives an electric shock.
    Anxiolytic drugs cause inertia with respect to these electroshocks and therefore treated mice more often overcome platelets than control ones. Mice, 45 minutes after the administration of the test substance, are placed. per minute into the chamber, and the number of shocks obtained is measured, which is compared to the number of shocks received by control animals. Results are expressed as a percentage of the increase in the number of shocks received by treated animals relative to control animals. Results are expressed as a percentage of the increase in the number of shots 5 received by treated animals.
    with respect to control animals (expressed as a% effect per dose) or at the dose limit (DP), which is a weaker dose that gives a significant effect. Toxicity.
    Finally, for some substances, DDS is given in mg / kg (oral administration),
    The results obtained in these various tests are summarized in the table below.
    The products according to the invention can be used in medicine for the treatment of neuropsychiatric disorders in humans, such as agonizing fear, states of reactionary depression and neurosis.
    The active principle is in a form suitable for oral, parenteral or endorectal use, for example, drops, grains, wafers, tablets, suppositories or solutions for injection.
    The dosage, depending on the treatment prescribed, can be from 2 to 100 mg per day.
    As an example, these medicaments; you can be in the following forms:
    Wafer
    CM 7119 mg2
    Tartaric acid, mg b
    Talc mg 107
    Tablet
    CM 7119 or 7120 mg 2
    Wine acid, mg 8
    Microcrystalline
    cellulose, 40 mg
    Lactose, mg68
    Stearate MD, mg 2
    权利要求:
    Claims (1)
    [1]
    1. Patent of the USSR No. 339043, cl. C 07 C 127/19, 1967.
    类似技术:
    公开号 | 公开日 | 专利标题
    US5607936A|1997-03-04|Substituted aryl piperazines as neurokinin antagonists
    RU2102387C1|1998-01-20|Derivatives of n-acyl-2,3-benzodiazepine, or their stereoisomers, or acid additive salts having biological activity connected with affection upon central nervous system and pharmacological active composition on their base
    DE2221558A1|1973-11-15|NEW BENZODIACEPINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
    CH631696A5|1982-08-31|METHOD FOR PRODUCING OLEFINIC DERIVATIVES FROM AMINO ACIDS.
    CH648553A5|1985-03-29|NEW 3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
    CA1161853A|1984-02-07|N-lower-alkyl 3-phenoxy-1-azetidine-carboxamides
    IL239119A|2017-09-28|Diazole lactams
    SU888820A3|1981-12-07|Method of preparing benzodiazepin derivatives
    US2862966A|1958-12-02|archo
    NZ209166A|1987-07-31|1-piperazinecarboxamides and pharmaceutical compositions
    HU191586B|1987-03-30|Process for preparing new derivatives of pyridazine and pyrimidine
    US3852292A|1974-12-03|2-|-imidazole-4,5-dicarboxylic acid and derivatives
    DD284025A5|1990-10-31|PROCESS FOR PREPARING IMIDAZO | PYRIDINE DERIVATIVES
    US3892772A|1975-07-01|Isomer of 1-|-1,2-cyclopropanedicarboximide and method of use
    EP0054839B1|1985-06-19|2-acylaminomethyl-1,4-benzodiazepines and their salts, methods of preparing them and pharmaceutical compositions containing them
    US4182760A|1980-01-08|Benzophenone anti-oximes, diazepin-N-oxides, and their use as pharmaceutical agents and as intermediates for pharmaceutical agents
    DE2525250C2|1985-02-14|N, N&#39;-phenylenedioxamic acid esters, processes for their production and pharmaceutical preparations which contain these compounds
    US4220776A|1980-09-02|N-|amides
    DE2107356A1|1971-08-26|Thieno square bracket on 2.3 square bracket on square bracket on 1.4 square bracket on diazepin 2 ones and processes for their production
    US3825533A|1974-07-23|N-carboxymethyl-n-substituted glycinate esters of 3-hydroxy-1,4-benzo-diazepin-2-ones
    US3637746A|1972-01-25|Process for preparing n-aryl-alpha-oxocyclopolymethylene amines an related compounds
    US3914246A|1975-10-21|Tri-substituted imidazoles
    US3989835A|1976-11-02|Method of using 6-substituted amino phenyl-2,3,5,6-tetra-hydro[2,1-b]thiazoles for controlling gastrointestinal nematodes
    US3584001A|1971-06-08|Certain n-substituted cyclobutane carboxamides
    DE2525164C2|1986-10-16|m-Phenylenedioxamic acid diesters, processes for their production and pharmaceutical preparations containing these compounds
    同族专利:
    公开号 | 公开日
    FR2350346B1|1980-11-21|
    NZ184012A|1981-11-19|
    ES458481A1|1978-04-01|
    GR63203B|1979-10-08|
    FR2350345B1|1980-07-18|
    CS207400B2|1981-07-31|
    FI771413A|1977-11-06|
    DE2719607A1|1977-11-17|
    ATA320177A|1979-10-15|
    SE431543B|1984-02-13|
    NO771560L|1977-11-08|
    DK195177A|1977-11-06|
    US4587245A|1986-05-06|
    EG12724A|1979-12-31|
    DD129446A5|1978-01-18|
    US4235897A|1980-11-25|
    AT356655B|1980-05-12|
    CS207399B2|1981-07-31|
    DE2719607C2|1987-07-16|
    IE44830L|1977-11-05|
    MX4720E|1982-08-13|
    AU2481377A|1978-11-09|
    JPS6137249B2|1986-08-22|
    FR2350345A1|1977-12-02|
    CA1083146A|1980-08-05|
    JPS5711317B2|1982-03-03|
    CH620912A5|1980-12-31|
    BE854249A|1977-11-04|
    NL7704911A|1977-11-08|
    NO149208B|1983-11-28|
    YU113977A|1982-08-31|
    PH12641A|1979-07-11|
    IL51998A|1981-05-20|
    PT66500A|1977-06-01|
    FR2350346A1|1977-12-02|
    SE7705182L|1977-11-06|
    HU177573B|1981-11-28|
    NO149208C|1984-03-07|
    SE432099B|1984-03-19|
    AU509147B2|1980-04-24|
    JPS52156882A|1977-12-27|
    DK195077A|1977-11-06|
    IL58648D0|1980-02-29|
    JPS52156883A|1977-12-27|
    IL51998D0|1977-07-31|
    IE44830B1|1982-04-07|
    NO813180L|1977-11-08|
    YU41818B|1988-02-29|
    JPS5781472A|1982-05-21|
    PT66500B|1978-10-13|
    SE7705183L|1977-11-06|
    ZA772628B|1978-03-29|
    CH620686A5|1980-12-15|
    AR219924A1|1980-09-30|
    DE2719608A1|1977-11-24|
    NL7704912A|1977-11-08|
    CS207398B2|1981-07-31|
    GB1538164A|1979-01-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US28315A|1860-05-15|Improvement in method of decomposing fats into fatty acids and glycerine |
    US3136815A|1959-12-10|1964-06-09|Hoffmann La Roche|Amino substituted benzophenone oximes and derivatives thereof|
    US3236838A|1964-06-09|1966-02-22|Hoffmann La Roche|Certain 1-substituted-benzodiazepin-2-one compounds|
    FR1497456A|1964-06-15|1967-10-13|Clin Byla Ets|Ortho-amino aryl ketimines, heterocyclic compounds attached to them and preparation of these various bodies|
    USRE28315E|1964-06-15|1975-01-21|Cooc.hi |
    US3812103A|1967-04-11|1974-05-21|Hoffmann La Roche|2,3-dihydro-1,4-benzodiazepines|
    CH498846A|1967-08-09|1970-11-15|Hoffmann La Roche|Process for the preparation of benzodiazepine derivatives|
    CH500997A|1967-08-09|1970-12-31|Hoffmann La Roche|Benzodiazepine derivs tranquillisers muscle relaxants|
    US3657223A|1969-01-17|1972-04-18|Hoffmann La Roche|Process for the preparation of benzodiazepin-2-one derivatives|
    IL33961A|1969-03-13|1973-03-30|Sparamedica Ag|Benzodiazepine aminoalkyl carboxylates,their preparation and pharmaceutical compositions containing them|
    US3718646A|1970-10-05|1973-02-27|Upjohn Co|N-lower alkenyl-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepine-1-carboxamides|
    IT1044223B|1972-08-09|1980-03-20|Zambeletti Spa L|I PROPARGIL 1 4 BENZODIAZEPINE|DE2900017A1|1978-01-10|1979-07-12|Clin Midy|3-ALCOXYCARBONYL BENZODIAZEPINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THEM|
    FR2460938B1|1979-07-12|1984-06-08|Cm Ind|
    DE3021107A1|1980-06-04|1981-12-17|Hoechst Ag, 6000 Frankfurt|CARBAMOYLOXYAMINO-1,4-BENZODIAZEPINE, METHOD FOR IRER PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THE SAME|
    JPS6038380A|1983-08-11|1985-02-27|Shionogi & Co Ltd|Improved synthesis of 1-piperidinyl-1,4-benzodiazepine|
    JPH04200396A|1990-11-30|1992-07-21|Sanwa Kagaku Kenkyusho Co Ltd|High-sensitivity enzymatic determination of hydrogen peroxide and reagent therefor|
    AU678503B2|1993-09-24|1997-05-29|Takeda Chemical Industries Ltd.|Condensed heterocyclic compounds and their use as squalene synthetase inhibitors|
    KR100668045B1|2005-08-17|2007-01-16|한국과학기술연구원|omega;-[2-ETHYLTHIO]ALKYLALKOXYSILANES AND THEIR PREPARATION METHODS|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB18492/76A|GB1538164A|1976-05-05|1976-05-05|Benzodiazepine derivatives|
    [返回顶部]